Objective:

To discuss the ongoing efforts and challenges surrounding clinical trial transparency, particularly in relation to the European Medicines Agency's (EMA) policies and legal battles.

Approach:

• Background: The issue of clinical trial transparency gained prominence with the publication of Ben Goldacre’s 'Bad Pharma' in September 2012, prompting the EMA to address transparency issues.
• EMA's Response: The EMA has developed an open access policy through public consultations, leading to the proactive release of clinical study reports.
• Legal Challenges: Recent court rulings have blocked the release of clinical trial data requested under the EU’s Transparency Regulation, citing concerns over commercially confidential information.

Key Findings:

• The EMA continues to advocate for transparency despite legal challenges from pharmaceutical companies, which have led to temporary halts in the release of certain clinical study reports.
• Recent court rulings have blocked the release of clinical trial data requested under the EU's Transparency Regulation, citing concerns over commercially confidential information.
• The EMA plans to appeal the court decisions, viewing them as an opportunity to test its new transparency rules.

Interpretation:

The EMA asserts that clinical reports should not be considered confidential in their entirety, allowing for redactions of commercially sensitive information.

Limitations:

• Ongoing legal battles may hinder the EMA's transparency efforts, as pharmaceutical companies resist the release of their data.
• Recent court rulings have temporarily blocked the release of clinical trial data, complicating the EMA's transparency initiatives.

Conclusion:

The EMA is committed to transparency but faces significant obstacles from legal rulings and industry resistance.

Sources:

• European Medicines Agency